吉西他滨联合奥沙利铂(GEMOX方案)治疗晚期恶性实体瘤的临床研究

Efficacy and toxicity of gemcitabine plus oxaliplatin in the treatment of advanced malignant solid tumors

目的:观察吉西他滨联合奥沙利铂(GEMOX方案)治疗晚期恶性实体瘤的近期疗效和不良反应。方法:30例晚期实体瘤患者,初治24例,复治6例,采用GEMOX方案:吉西他滨1000mg/m2,d1、d8静脉滴注;草酸铂130mg/m2,d1静脉滴注。21天-28天为1周期。结果:28例可评价疗效的患者中CR0例,PR 7例,NC14例,PD7例,总有效率为25.0%,疾病控制率75.0%。中位生存期8.3个月,1年生存率22.7%。主要毒副反应为骨髓抑制、恶心和呕吐。结论:吉西他滨联合奥沙利铂治疗晚期恶性实体瘤有较好的临床疗效,毒副反应轻,患者易耐受。

Objective：To observe the efficacy and toxicity of gemcitabine plus oxaliplatin （GEMOX regimen） in the treatment of advanced malignant solid tumors. Methods：Among 30 cases ,24 patients were untreated ,6 were pre treated tumor cases. They were all treated with GEMOX regimen. Oxaliplatin （ 130mg/m^2 ） was administered by in- travenous infusion on day 1 and gemcitabine （ 1,000mg/m^2 ） was given by intravenous infusion on days 1 and 8. The regimen was repeated every 21 - 28 days. All patients received 2 or more cycles therapies. Results ： Of the 28 evaluable patients,7 achieved partial remission, 14 stable disease, and 7 progressive disease. The response rate （ C R ＋ PR） was 25.0%. Median overall survival was 8.3 months with the 1 - year survival rate of 22.7%. The major toxicity included bone marrow depression, nausea and vomiting. Conclusion： The regimen of gemcitabine in combination with oxaliplatin is effective, safe and well tolerated for advanced malignant solid tumors.